Drugs / RG002C0106
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07445906 | Mar → Dec 2026 expected | IgA glomerulonephritis, impaired renal function disease | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06494527 | Oct 2024 → Aug 2026 overdue | — | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07305974 | Sep 2025 → Mar 2029 expected | IgA glomerulonephritis | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG002C0106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07305974 ↗ |
| Action | Inhibit | “inhibit the expression of C3 protein” NCT06494527 ↗ |
| Modality | Small interfering RNA (siRNA) | “is a siRNA drug” NCT06494527 ↗ |
| Route | Subcutaneous | “receive subcutaneous injection for administration” NCT06494527 ↗ |
| Target | C3 | “targeting complement C3” NCT06494527 ↗ |